Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIVO Microdosing of Motolimod and Nivolumab in HNSCC
NCT04272333Phase 1Terminated
- Sponsor
- Presage Biosciences
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of motolimod in head and neck squamous cell carcinoma (HNSCC), sponsored by Presage Biosciences. Primary endpoint: Quantification of Cell Death and Immune Cell Biomarkers by Immunohistochemistry (IHC) and In-Situ Hybridization (ISH). Started Oct 2021; status: terminated.
02
Drugs
motolimod
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04272333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272333.